The Q1 beat and reiterated FY2027 guidance confirm the Med Tech growth trajectory is on track. Watch for the CEO transition on November 2 and any updates on tariff refund sustainability, which boosted gross margin by 160 bps this quarter. The NanoKnife RELIEF BPH study IDE approval opens a new addressable market beyond oncology.
Price Chart
Executive Summary
AngioDynamics reported Q1 FY2027 results with net sales of $80.9M (+6.9% YoY), beating revenue consensus of $84.3M by 4.0%. Adjusted EPS of -$0.04 beat the -$0.07 consensus by 42.9%. Med Tech segment grew 13.2% YoY, marking the eighth consecutive quarter of double-digit growth. Gross margin expanded 410 bps to 59.4%, benefiting from tariff refunds. The company reiterated its FY2027 guidance. CEO Jim Clemmer announced retirement, with Eric Honroth appointed as successor effective November 2, 2026.
Key Financial Metrics
Key Facts
- Net sales of $80.9M, +6.9% YoY, vs consensus $84.3M (4.0% beat)
- Adjusted EPS -$0.04 vs consensus -$0.07 (42.9% beat)
- Med Tech segment sales $39.9M, +13.2% YoY (8th consecutive quarter of double-digit growth)
- GAAP gross margin 59.4%, +410 bps YoY; excluding tariff refunds would have been 57.8%
- Adjusted EBITDA $5.0M vs $2.2M in prior year quarter
- Cash used in operations $15.3M; cash balance $34.0M, debt-free balance sheet
- FY2027 guidance reiterated: net sales $336M-$341M, Med Tech growth 12%-15%, adjusted EPS ($0.29)-($0.24)
- CEO Jim Clemmer retiring; Eric Honroth appointed President and CEO effective November 2, 2026
- FDA IDE approval received for RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia
Financial Impact
Revenue beat of ~$3.4M vs consensus; EPS beat of $0.03 vs consensus; gross margin expansion of 410 bps YoY
Risk Factors
- CEO transition risk despite planned succession
- Tariff refunds may not recur; gross margin expected to be lower in H2 FY2027
- Cash burn of $15.3M in operating activities; cash balance declining to $34.0M
- Med Device segment growth remains flat at 1.4%
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-039020 |
| Document: ef20083493_8k.htm | 0001140361-26-039020 |
| Document: ef20083493_ex99-2.htm | 0001140361-26-039020 |
| Document: 0001140361-26-039020-index-headers.html | 0001140361-26-039020 |
| Document: 0001140361-26-039020-index.html | 0001140361-26-039020 |
| Document: 0001140361-26-039020.txt | 0001140361-26-039020 |
| 8-K Data (Synthetic) | 0001140361-26-039020 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | DEFA14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | DEF 14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Jul 14, 2026 15w ago | 8-K | $13.00 $13.71 | ▲ +5.46% | ▲ +6.76% | $12.26 (−5.69%) |
Apr 2, 2026 29w ago | 8-K | $10.31 $9.80 | ▼ −4.95% | ▼ −8.57% | $12.26 (+18.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers